Skip to main navigation Skip to main content
  • KSBMR

JBM : Journal of Bone Metabolism

OPEN ACCESS
ABOUT
BROWSE ARTICLES
EDITORIAL POLICIES
FOR CONTRIBUTORS

Page Path

3
results for

"Zoledronic acid"

Article category

Keywords

Publication year

Authors

"Zoledronic acid"

Original Articles

Zoledronate Therapy in Osteogenesis Imperfecta: Perspectives in Indonesia Tertiary Hospital
Tri Wahyu Martanto, Aliefio Japamadisaw, Dian Nurhayati, Rob G. H. H. Nelissen
J Bone Metab 2024;31(4):290-295.
Published online November 4, 2024
DOI: https://doi.org/10.11005/jbm.24.767
Background
Osteogenesis imperfecta (OI) is a rare disease with an estimated incidence of between 1/25,000 and 1/10,000 globally. The main treatment for OI is the administration of bisphosphonate drugs. Research on clinical, radiographic, and biochemical markers to monitor patients with OI treated with zoledronate can be challenging in countries in which patients have limited national health insurance. We aimed to examine patients with OI treated in Indonesia with a minimum follow-up period of 2 years.
Methods
An observational study was conducted of all patients with OI treated with zoledronate between 2021 and 2023 at a tertiary hospital in Indonesia. We evaluated the paediatric quality of life (PedsQL), bone mineral density (BMD), and alkaline phosphatase (ALP) level before and after zoledronate treatment. To monitor safety, serum creatinine and calcium levels were also measured.
Results
Eleven boys (55%) and nine girls (45%), with an average age of 6.9 years (range, 4–17 years), were included. After 2 years of zoledronate treatment, the total PedsQL score increased from 66.7 to 76.9 (P=0.0001) and the mean lumbar and total body BMD increased from 0.467 and 0.501 to 0.599 g/cm2, and 0.626 g/cm2 (P=0.001), respectively. The ALP level decreased from 310.6 to 186.4 mg/mL (P=0.0001). Neither serum creatinine (P=0.586) nor calcium (P=0.53) levels changed from the pre-treatment to 2 years post-treatment time points.
Conclusions
Zoledronate was safe and effective for the treatment of OI. There were significant improvements in the quality of life and BMD in patients with OI. The ALP level decreased, but serum creatinine and calcium levels were not affected by zoledronate.

Citations

Citations to this article as recorded by  Crossref logo
  • 1. Fracture risk assessment by dual-energy absorptiometry in osteogenesis imperfecta: A systematic review of measurement sites and its predictive value
    Karlijn Scheepens, Suzanne den Haan, Kelly Warmink, Ralph Sakkers, Anne Spaans, Wouter Nijhuis, Harrie Weinans
    Bone Reports.2026; 30: 101929.     CrossRef
  • 2. Health-Related Quality of Life and Fatigue in Patients with Osteogenesis Imperfecta
    Filiz Mercan Sarıdaş, Erhan Hocaoğlu, Müge Yaşar, Kadircan Karatoprak, Güven Özkaya, Soner Cander, Erdinç Ertürk, Canan Ersoy, Özen Öz Gül
    Healthcare.2026; 14(12): 1620.     CrossRef
  • 3,677 View
  • 67 Download
  • Crossref
Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
Sung Hye Kong, Jung Hee Kim, Sang Wan Kim, Ae Jin Jeong, Song-Hee Lee, Sang-Kyu Ye, Chan Soo Shin
J Bone Metab 2022;29(2):93-101.
Published online May 31, 2022
DOI: https://doi.org/10.11005/jbm.2022.29.2.93
Background
A rapid increase in bone turnover and bone loss has been observed in response to the discontinuation of denosumab. It led to an acute increase in the fracture risk, similar to that observed in the untreated patients. We aimed to investigate the effect of denosumab on osteoclast (OC) precursor cells compared to that of zoledronate.
Methods
The study compared the effects of denosumab (60 mg/24-week) and zoledronate (5 mg/48-week) over 48 weeks in postmenopausal women with osteoporosis. From patients’ peripheral mononuclear cells, CD14+/CD11b+/vitronectin receptor (VNR)- and CD14+/CD11b+/VNR+ cells were isolated using fluorescent-activated cell sorting, representing early and late OC precursors, respectively. The primary endpoint was the changes in OC precursors after 48 weeks of treatment.
Results
Among the 23 patients, 11 were assigned to the denosumab group and 12 to the zoledronate group (mean age, 69 years). After 48 weeks, the changes in OC precursors were similar between and within the groups. Serum C-terminal telopeptide of type I collagen levels were inversely correlated with OC precursor levels after denosumab treatment (r=-0.72, P<0.001). Lumbar spine, femur neck, and total hip bone mineral density (BMD) increased in both groups. Lumbar spine BMD increased more significantly in the denosumab group than in the zoledronate group.
Conclusions
Denosumab and zoledronate treatments induced similar changes in OC precursors. During denosumab treatment, old age and suppressed bone turnover were associated with increased OC precursor cell populations. Further validation studies with prospective designs are required.

Citations

Citations to this article as recorded by  Crossref logo
  • 1. Efficacy and Safety of Denosumab and Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis—A Comparative Study of Bone Metabolism, Bone Density, and Sex Hormone Levels
    Huiling Tang, Jinyan Chen, Xufeng Fan
    Journal of Applied Toxicology.2026; 46(5): 1530.     CrossRef
  • 2. Real-world rebound pattern of serum collagen type I C-telopeptide after denosumab discontinuation and zoledronate rescue in postmenopausal osteoporosis and cancer treatment-induced bone loss
    Federico Aldegheri, Angelo Fassio, Matteo Appoloni, Denise Rotta, Francesca Ruzzon, Davide Bertelle, Giovanni Adami, Davide Gatti, Maurizio Rossini, Ombretta Viapiana
    Osteoporosis International.2026; 37(4): 983.     CrossRef
  • 3. Progress on novel compounds for the treatment of bone metabolism-related disorders: focus on osteoporosis and beyond
    Yeqiong Song, Ruixing Zhang, Xinyue Zhang, Jingkai Wang, Jinyang Chen, Li Li
    Frontiers in Chemistry.2026;[Epub]     CrossRef
  • 4. The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation
    Marian Schini, Fatma Gossiel, Tanya Saini, Peter Banda, Rachel Ward, Tatiane Vilaca, Richard Eastell, Andreas Fontalis
    Journal of Bone and Mineral Research.2025; 40(3): 301.     CrossRef
  • 5. Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures
    Shejil Kumar, Mawson Wang, Albert S Kim, Jacqueline R Center, Michelle M McDonald, Christian M Girgis
    Journal of Bone and Mineral Research.2025; 40(9): 1017.     CrossRef
  • 6. Denosumab Withdrawal and Rebound Bone Resorption: Molecular Mechanisms and Approaches for Treatment
    Anish Rajamohanan Jalaja, Aswathy Nair
    Current Stem Cell Reports.2025;[Epub]     CrossRef
  • 7. Positive und negative (Neben)Effekte bei Osteoporose-Sequenztherapie
    Barbara Obermayer-Pietsch, Ines Fößl, Friederike Thomasius
    Osteologie.2024; 33(02): 80.     CrossRef
  • 8. Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)
    N. Yu. Velts, O. V. Velts, R. N. Alyautdin
    Safety and Risk of Pharmacotherapy.2024; 12(2): 190.     CrossRef
  • 9. Cellular signatures in human blood track bone mineral density in postmenopausal women
    Kaichi Kaneko, Jefferson Tsai, Deniece Meñez, Brian Oh, Andrew Junwoo Suh, Seyeon Bae, Masataka Mizuno, Akio Umemoto, Eugenia Giannopoulou, Takayuki Fujii, Yaxia Zhang, Emily M. Stein, Richard S. Bockman, Kyung-Hyun Park-Min
    JCI Insight.2024;[Epub]     CrossRef
  • 10. Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment
    Chiao-Ling Chen, Jian-Ying Wang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • 11. Denosumab Can Prevent Collapse in Patients with Early‐Stage Steroid‐Induced Osteonecrosis of the Femoral Head by Inhibiting Osteoclasts and Autophagy
    Bo Liu, Feng Gao, Xiaofei Xiu, Tao Wu, Zeming Liu, Bingshi Zhang, Sikai Liu, Yongtai Han
    Orthopaedic Surgery.2023; 15(1): 256.     CrossRef
  • 12. Long-term and sequential treatment for osteoporosis
    Ines Foessl, Hans P. Dimai, Barbara Obermayer-Pietsch
    Nature Reviews Endocrinology.2023; 19(9): 520.     CrossRef
  • 7,588 View
  • 152 Download
  • Crossref
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
Tarun Kadaru, Amal Shibli-Rahhal
J Bone Metab 2021;28(1):51-58.
Published online February 28, 2021
DOI: https://doi.org/10.11005/jbm.2021.28.1.51
Background
Bone mineral density (BMD) declines when zoledronic acid (ZA) is administered. This case series describes the patterns of change in BMD when 1 or 2 doses of ZA are administered after denosumab.
Methods
Twelve patients who received at least 2 doses of denosumab followed by at least 1 dose of ZA and who had a dual energy X-ray absorptiometry (DXA) scan at the end of denosumab and 1 year after the first dose of ZA were included. We excluded patients with bone cancer or conditions affecting bone metabolism, including hyperparathyroidism, rickets, osteogenesis imperfecta, rheumatologic disorders, fibrous dysplasia, Paget’s disease of bone, untreated hyperthyroidism, chronic kidney disease, liver cirrhosis, malabsorption, ongoing corticosteroid therapy, and aromatase inhibitor use.
Results
There was a significant decline in BMD at the femoral neck within 1 year of the first ZA dose and a non-significant downward trend in the hip and lumbar spine. This trend was more severe in patients with osteoporosis at the time of drug transition. No increase in clinical vertebral fractures was observed. BMD seemed to stabilize in a smaller number of patients who received a second dose of ZA and had a DXA scan 1 year later.
Conclusions
A single dose of ZA administered approximately 6 months after denosumab leads to some BMD loss, mostly within 1 year of ZA administration, particularly in patients with osteoporosis at the time of denosumab discontinuation.

Citations

Citations to this article as recorded by  Crossref logo
  • 1. Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?
    Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang
    Clinical Pharmacology & Therapeutics.2026; 120(2): 334.     CrossRef
  • 2. Osteoporosis as a chronic disease: an expert narrative review and practical recommendations on long-term management and sequential therapy after denosumab discontinuation
    Sandro Giannini, Davide Gatti, Andrea Giusti, Gregorio Guabello, Stefano Lello, Andrea Palermo, Luigi Gennari
    Endocrine.2026;[Epub]     CrossRef
  • 3. Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures
    Shejil Kumar, Mawson Wang, Albert S Kim, Jacqueline R Center, Michelle M McDonald, Christian M Girgis
    Journal of Bone and Mineral Research.2025; 40(9): 1017.     CrossRef
  • 4. Effectiveness of Sequential Treatment with Zoledronic Acid Following Discontinuation of Denosumab in Osteoporosis: A Narrative Review
    Hong Ouyang, Fan Yang, Wenzuo Wei, Wei Wang
    Drug Design, Development and Therapy.2025; Volume 19: 10013.     CrossRef
  • 5. Asia-Pacific consensus on long-term and sequential therapy for osteoporosis
    Ta-Wei Tai, Hsuan-Yu Chen, Chien-An Shih, Chun-Feng Huang, Eugene McCloskey, Joon-Kiong Lee, Swan Sim Yeap, Ching-Lung Cheung, Natthinee Charatcharoenwitthaya, Unnop Jaisamrarn, Vilai Kuptniratsaikul, Rong-Sen Yang, Sung-Yen Lin, Akira Taguchi, Satoshi Mo
    Osteoporosis and Sarcopenia.2024; 10(1): 3.     CrossRef
  • 6. Zoledronic acid relieves steroid-induced avascular necrosis of femoral head via inhibiting FOXD3 mediated ANXA2 transcriptional activation
    Yu Lin, Min Chen, Wenbin Guo, Shengliang Qiu, Lihui Chen, Wenge Liu
    Bone.2024; 188: 117222.     CrossRef
  • 7. A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis
    Zhanna Belaya, Liudmila Rozhinskaya, Ivan Dedov, Oksana Drapkina, Valentin Fadeev, Olga Golounina, Olga Lesnyak, Elizaveta Mamedova, Galina Melnichenko, Alexey Petraikin, Svetlana Rodionova, Irina Skripnikova, Olga Tkacheva, Natalia Toroptsova, Svetlana Y
    Osteoporosis International.2023; 34(3): 429.     CrossRef
  • 8. Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
    Christian Horst Tonk, Sarah Hani Shoushrah, Patrick Babczyk, Basma El Khaldi-Hansen, Margit Schulze, Monika Herten, Edda Tobiasch
    International Journal of Molecular Sciences.2022; 23(3): 1393.     CrossRef
  • 9. Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis
    Namki Hong, Sungjae Shin, Seunghyun Lee, Kyoung Jin Kim, Yumie Rhee
    Calcified Tissue International.2022; 111(1): 47.     CrossRef
  • 10. Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
    Jung-Wee Park
    Journal of Bone Metabolism.2021; 28(4): 339.     CrossRef
  • 9,903 View
  • 222 Download
  • Crossref